CCR4 and Sezary syndrome: The anti-CCR4 monoclonal antibody, Mogamulizumab, also shows promise in treatment of peripheral T-cell lymphoma and cutaneous T-cell lymphomas like mycosis fungoides and Sezary syndrome, by depleting CCR4+ malignant cells and CCR4+ Tregs (175, 176).